Biblio
“Designing an Internet-Based Multidomain Intervention for the Prevention of Cardiovascular Disease and Cognitive Impairment in Older Adults: The HATICE Trial.”, J Alzheimers Dis, vol. 62, no. 2, pp. 649-663, 2018.
, “Dementia Care in the Time of COVID-19 Pandemic.”, J Alzheimers Dis, vol. 76, no. 2, pp. 475-479, 2020.
, “Dementia Care in Times of COVID-19: Experience at Fundació ACE in Barcelona, Spain.”, J Alzheimers Dis, vol. 76, no. 1, pp. 33-40, 2020.
, “Dementia in the COVID-19 Period.”, J Alzheimers Dis, vol. 75, no. 4, pp. 1071-1072, 2020.
, “Telemedicine for Delivery of Care in Frontotemporal Lobar Degeneration During COVID-19 Pandemic: Results from Southern Italy.”, J Alzheimers Dis, vol. 76, no. 2, pp. 481-489, 2020.
, “Characterizing Limbic-Predominant Age-Related TDP-43 Encephalopathy Without Alzheimer's Disease and Lewy Body Dementia in the Oldest Old: A Case Series.”, J Alzheimers Dis, vol. 96, no. 1, pp. 113-124, 2023.
, “Homotaurine Effects on Hippocampal Volume Loss and Episodic Memory in Amnestic Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 3, pp. 807-16, 2016.
, “Propagation of tau pathology in a model of early Alzheimer's disease.”, Neuron, vol. 73, no. 4, pp. 685-97, 2012.
, “Tau in Alzheimer disease and related tauopathies.”, Curr Alzheimer Res, vol. 7, no. 8, pp. 656-64, 2010.
, “Hyperactivity with Agitative-Like Behavior in a Mouse Tauopathy Model.”, J Alzheimers Dis, vol. 49, no. 3, pp. 783-95, 2016.
, “Tauopathies: Mechanisms and Therapeutic Strategies.”, J Alzheimers Dis, vol. 61, no. 2, pp. 487-508, 2018.
, “SIRT1 Deacetylates SC35 and Suppresses Its Function in Tau Exon 10 Inclusion.”, J Alzheimers Dis, vol. 61, no. 2, pp. 561-570, 2018.
, “In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1037-1052, 2018.
, “Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1201-1219, 2018.
, “NLRP3 Inflammasome: A Starring Role in Amyloid-β- and Tau-Driven Pathological Events in Alzheimer's Disease.”, J Alzheimers Dis, vol. 83, no. 3, pp. 939-961, 2021.
, “Cognitive and Neuropsychological Profiles in Alzheimer's Disease and Primary Age-Related Tauopathy and the Influence of Comorbid Neuropathologies.”, J Alzheimers Dis, vol. 92, no. 3, pp. 1037-1049, 2023.
, “Characterizing Limbic-Predominant Age-Related TDP-43 Encephalopathy Without Alzheimer's Disease and Lewy Body Dementia in the Oldest Old: A Case Series.”, J Alzheimers Dis, vol. 96, no. 1, pp. 113-124, 2023.
, “The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 49, no. 2, pp. 547-60, 2016.
, “Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.”, Lancet Neurol, vol. 12, no. 2, pp. 207-16, 2013.
, “Propagation of tau pathology in a model of early Alzheimer's disease.”, Neuron, vol. 73, no. 4, pp. 685-97, 2012.
, “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
, “Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.”, Proc Natl Acad Sci U S A, vol. 108, no. 14, pp. 5819-24, 2011.
, “Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.”, Ann Neurol, vol. 70, no. 4, pp. 532-40, 2011.
, “Tau in Alzheimer disease and related tauopathies.”, Curr Alzheimer Res, vol. 7, no. 8, pp. 656-64, 2010.
, “Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo.”, J Alzheimers Dis, vol. 50, no. 1, pp. 77-87, 2016.
,